published meta-analysis   sensitivity analysis   studies

chloroquine and derivatives in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsBCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.68 [0.22; 2.08] COVID-PEP-Post exposure (Boulware), 2020 0.98 [0.02; 49.67] PATCH-cohort 3 PreP (Abella), 2020 1.00 [0.02; 51.16] 0.71[0.25; 2.02]BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, COVID-PEP-Post exposure (Boulware), 2020, PATCH-cohort 3 PreP (Abella), 202030%3,450moderatenot evaluable hospitalizationdetailed resultsCOVID-PEP-Post exposure (Boulware), 2020 0.98 [0.06; 15.77] Rojas-Serrano, 2021 1.05 [0.02; 53.69] 1.00[0.10; 9.70]COVID-PEP-Post exposure (Boulware), 2020, Rojas-Serrano, 202120%948lownot evaluable symptomatic Covid-19detailed resultsBarnabas RV, 2020 1.27 [0.79; 2.04] COVID PREP (HCQ 1x week, Rajasingham), 2020 0.65 [0.18; 2.33] COVID PREP HCQ (2x week, Rajasingham), 2020 1.18 [0.40; 3.50] COVID-PEP-Post exposure (Boulware), 2020 0.84 [0.55; 1.27] HERO-HCQ (Naggie), 2021 0.75 [0.49; 1.15] Rojas-Serrano, 2021 0.16 [0.02; 1.38] 0.89[0.68; 1.17]Barnabas RV, 2020, COVID PREP (HCQ 1x week, Rajasingham), 2020, COVID PREP HCQ (2x week, Rajasingham), 2020, COVID-PEP-Post exposure (Boulware), 2020, HERO-HCQ (Naggie), 2021, Rojas-Serrano, 2021614%5,113lownot evaluable asymptomatic COVID casedetailed resultsEPICOS (Polo), 2022 0.96 [0.49; 1.90] 0.96[0.49; 1.90]EPICOS (Polo), 202210%454NAnot evaluable infection (PCR positive symptomatic or not)detailed resultsBarnabas RV, 2020 1.10 [0.73; 1.66] BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.86 [0.52; 1.42] COVID PREP (HCQ 1x week, Rajasingham), 2020 0.73 [0.45; 1.19] COVID PREP HCQ (2x week, Rajasingham), 2020 0.74 [0.45; 1.21] COVID-PEP-Post exposure (Boulware), 2020 1.21 [0.49; 2.94] EPICOS (Polo), 2022 0.87 [0.47; 1.62] HERO-HCQ (Naggie), 2021 0.75 [0.49; 1.15] PATCH-cohort 3 PreP (Abella), 2020 0.95 [0.23; 3.98] Rojas-Serrano, 2021 0.16 [0.02; 1.38] 0.85[0.70; 1.02]Barnabas RV, 2020, BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, COVID PREP (HCQ 1x week, Rajasingham), 2020, COVID PREP HCQ (2x week, Rajasingham), 2020, COVID-PEP-Post exposure (Boulware), 2020, EPICOS (Polo), 2022, HERO-HCQ (Naggie), 2021, PATCH-cohort 3 PreP (Abella), 2020, Rojas-Serrano, 202190%5,692lownot evaluable serious adverse eventsdetailed resultsBarnabas RV, 2020 1.04 [0.15; 7.40] BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 0.89 [0.44; 1.82] PATCH-cohort 3 PreP (Abella), 2020 1.00 [0.02; 51.16] 0.91[0.47; 1.76]Barnabas RV, 2020, BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, PATCH-cohort 3 PreP (Abella), 202030%3,458moderatenot evaluable adverse eventsdetailed resultsBarnabas RV, 2020 1.58 [1.06; 2.37] BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020 20.26 [15.67; 26.20] COVID PREP (HCQ 1x week, Rajasingham), 2020 0.59 [0.44; 0.79] COVID PREP HCQ (2x week, Rajasingham), 2020 2.02 [1.52; 2.70] COVID-PEP-Post exposure (Boulware), 2020 3.32 [2.33; 4.72] Rojas-Serrano, 2021 1.64 [0.78; 3.42] 2.45[0.77; 7.81]Barnabas RV, 2020, BCN PEP-CoV-2-Study 1 (Mitja NEJM), 2020, COVID PREP (HCQ 1x week, Rajasingham), 2020, COVID PREP HCQ (2x week, Rajasingham), 2020, COVID-PEP-Post exposure (Boulware), 2020, Rojas-Serrano, 2021699%6,130lownot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-03-28 15:29 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 508,656,657,832 - roots T: 290